ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2019
Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis from the US-based Corrona Psoriasis Registry.
Article in Journal of the European Academy of Dermatology and Venereology : JEADV, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Psoriatic arthritis screening: A systematic literature review and experts' recommendations.PloS one · 2021Pooled it
- Longitudinal Performance of the Psoriasis Epidemiology Screening Tool (PEST) in Canada and Latin America: Results from the Prospective, Observational, 5-Year PURE Registry.Dermatology and therapy · 2026Article
- Challenging the Dogma That Psoriasis Skin Lesions Occur Before Arthritis.International journal of dermatology · 2025Article
- Analysis of PEST Questionnaire Responses in Patients with Psoriasis in Daily Practice: Results from a Single-Center of Psoriasis in the Czech Republic.Dermatology and therapy · 2025Article
- Prevalence of tobacco smoking and its association with disease severity and psoriatic arthritis among patients with nail psoriasis in China: a cross-sectional study.Frontiers in medicine · 2025Article
- Similar rates of new psoriatic arthritis diagnoses in a dedicated psoriatic disease triage clinic, regardless of referral route.Rheumatology advances in practice · 2025Article
- MAPK14 as a key gene for regulating inflammatory response and macrophage M1 polarization induced by ferroptotic keratinocyte in psoriasis.Inflammation · 2024Article
- Impact of Disease Factors of Patients with Psoriasis and Psoriatic Arthritis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis Registry.Dermatology and therapy · 2024Article
- Perspectives of Japanese patients on psoriatic disease burden: Results from "Psoriasis and Beyond," the Global Psoriatic Disease Survey.The Journal of dermatology · 2024Article
- The ATTRACT study: screening for the early identification of axial psoriatic arthritis in a cohort of Italian psoriatic patients.Rheumatology (Oxford, England) · 2024Article
- Inflammatory Skin Diseases: Focus on the Role of Suppressors of Cytokine Signaling (SOCS) Proteins.Cells · 2024Review
- Relationship Between Family History and Quality of Life in Patients with Psoriasis: A Cross-Sectional Study from China.Clinical, cosmetic and investigational dermatology · 2024Article
- Extra-musculoskeletal manifestations driving the therapeutic decision-making in patients with Spondyloarthritis: a 12-month follow-up prospective cohort study.Advances in rheumatology (London, England) · 2023Article
- Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors.Dermatology and therapy · 2023Review
- Impact of Psoriatic Disease on Quality of Life: Interim Results of a Global Survey.Dermatology and therapy · 2022Article
- Time to transition from psoriasis to psoriatic arthritis: A population-based study.Seminars in arthritis and rheumatism · 2022Article
- Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review.Frontiers in immunology · 2022Review
- Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas' Psoriasis Registry.Dermatology and therapy · 2022Article
- [Psoriatic arthritis: important aspects for the dermatological practice].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2021Review
- Longitudinal analysis of the patient pathways to diagnosis of psoriatic arthritis.Arthritis research & therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 3 countries.
Funding
Abstract
backgroundDespite increasing awareness of the disease, rates of undiagnosed psoriatic arthritis (PsA) are high in patients with psoriasis (PsO). The validated Psoriasis Epidemiology Screening Tool (PEST) is a five-item questionnaire developed to help identify PsA at an early stage.
objectivesTo assess the risk of possible undiagnosed PsA among patients with PsO and characterize patients based on PEST scores.
methodsThis study included all patients enrolled in the Corrona PsO Registry with data on all five PEST questions. Demographics, clinical characteristics and patient-reported outcomes were compared in Corrona PsO Registry patients with PEST scores ≥3 and <3 using t-tests for continuous variables and chi-squared tests for categorical variables; scores ≥3 may indicate PsA.
resultsOf 1516 patients with PsO, 904 did not have dermatologist-reported PsA; 112 of these 904 patients (12.4%) scored ≥3 and were significantly older, female, less likely to be working, and had higher BMI than patients with scores <3. They also had significantly longer PsO duration, were more likely to have nail PsO and had worse health status, pain, fatigue, Dermatology Life Quality Index and activity impairment.
conclusionsImproved PsA screening is needed in patients with PsO because the validated PEST identified over one-tenth of registry patients who were not noted to have PsA as having scores ≥3, who could have had undiagnosed PsA. Appropriate, earlier care is important because these patients were more likely to have nail PsO, worse health-related quality of life and worse activity impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.